{"id":"tp-40679","type":"article-newspaper","title":"J&J Reports 77% Response Rate in HPV-Unrelated Head and Neck Cancer Group","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/40679","datePublished":"2026-10-25T22:09:54.000Z","dateModified":"2026-10-25T22:09:54.000Z","language":"en","abstract":"The rate was 66% across all 29 evaluable participants. A randomized Phase 3 study will compare the regimen with pembrolizumab, platinum chemotherapy and 5-fluorouracil.","section":"Business","references":[]}